 |
인쇄하기
취소
|
KFDA recommends not to use dibutylphthalate
The Korea Food and Drug Administration has recently instructed pharmaceutical firms to replace dibutylphthalate (DBP) owing to the possible risk of adverse reactions.
Manufacturers of 37 medicines containing DBP as a pharmaceutical excipient, such as Boehringer Ingelheim’s Dulcolax, will be obliged to use other substance instead of DBP until December 28, 2010.
The KFDA also issued a cauti...
Manufacturers of 37 medicines containing DBP as a pharmaceutical excipient, such as Boehringer Ingelheim’s Dulcolax, will be obliged to use other substance instead of DBP until December 28, 2010.
The KFDA also issued a cauti...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.